Neuren PharmaceuticalsNeuren Pharmaceuticals
  • Home
  • About Us
    • Company Overview
    • Company Values
    • Board of Directors
    • Management
    • Corporate Directory
  • Product development
    • Product Development Pipeline
    • The science behind Neuren's products
    • Trofinetide (also known as NNZ-2566) in Rett Syndrome
    • Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
    • NNZ-2591 in Phelan-McDermid syndrome
    • NNZ-2591 in Angelman syndrome
    • NNZ-2591 in Pitt Hopkins syndrome
    • NNZ-2591 in Prader-Willi syndrome
  • Investor Information
    • Welcome
    • Share Price Information
    • Shareholder Services
    • Investor presentations, audio, video
    • Corporate Governance
    • Analyst Coverage
    • Corporate Directory
  • News & Reports
    • ASX Announcements
    • Annual and Interim Reports
    • Scientific presentations
    • Email Alerts
    • Publications
  • Contact Us
    • Contact Us
    • Email Alerts

Home > Investor Information > Investor presentations, audio, video
Font Smaller Font larger Print Page

Investor presentations, audio, video


 
9-May-2022    Acadia Q1 2022 earnings call transcript  
 
4-Apr-2022    Australian Financial Review article 4 Apr 2022  
 
25-Feb-2022    Investor webinar, 25 February 2022  
 
10-Dec-2021    AusBiz interview 8 December 2021  
 
2-Jul-2021    Peak TV interview 2 July 2021  
 
29-Jun-2021    MST Access Australian Micro & Small Caps Conference 2021 15 June 2021  
 
29-Jun-2020    AGM Chairman's Address and CEO Presentation  
 
   Sign up to Email Alerts Copyright © 2022 Neuren Pharmaceuticals   | Privacy | Site Map | Search
Site by IRM